Doravirine + tenofovir DF + lamivudine

DRUG2 trials

Sponsors

ANRS, Emerging Infectious Diseases, Instituto Mexicano del Seguro Social

Conditions

HIVHIV Associate Weight LossHIV-1 InfectionHIV-1-infectionIntegrase Inhibitors, HIV; HIV PROTEASE INHIBWeight ChangeWeight Loss

Phase 3

DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection

RecruitingNCT06203132

ANRS, Emerging Infectious DiseasesHIV-1-infection

Start: 2025-01-27End: 2027-11-30Target: 610Updated: 2026-01-07

Phase 4

Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI

RecruitingNCT06602622

Instituto Mexicano del Seguro SocialHIV, HIV-1 Infection, HIV Associate Weight Loss +3

Start: 2024-08-14End: 2025-11-14Target: 108Updated: 2024-09-19

Related Papers

Brief Report: Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD Trials

JAIDS Journal of Acquired Immune Deficiency Syndromes2025-01-031 citations